Doliver Advisors LP Cuts Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Doliver Advisors LP cut its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 8.2% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 74,328 shares of the biotechnology company’s stock after selling 6,672 shares during the period. Doliver Advisors LP’s holdings in BioCryst Pharmaceuticals were worth $559,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Principal Financial Group Inc. raised its holdings in BioCryst Pharmaceuticals by 1,058.1% in the 3rd quarter. Principal Financial Group Inc. now owns 411,414 shares of the biotechnology company’s stock worth $3,127,000 after acquiring an additional 375,890 shares during the last quarter. Exome Asset Management LLC purchased a new position in shares of BioCryst Pharmaceuticals in the third quarter worth $1,493,000. Franklin Resources Inc. lifted its holdings in shares of BioCryst Pharmaceuticals by 177.8% during the third quarter. Franklin Resources Inc. now owns 263,748 shares of the biotechnology company’s stock valued at $1,968,000 after purchasing an additional 168,790 shares in the last quarter. Sanctuary Advisors LLC increased its holdings in BioCryst Pharmaceuticals by 78.3% in the 3rd quarter. Sanctuary Advisors LLC now owns 47,389 shares of the biotechnology company’s stock worth $360,000 after buying an additional 20,818 shares in the last quarter. Finally, SkyView Investment Advisors LLC raised its position in BioCryst Pharmaceuticals by 30.0% in the 3rd quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the biotechnology company’s stock worth $99,000 after buying an additional 3,000 shares during the last quarter. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Price Performance

Shares of NASDAQ:BCRX traded up $0.22 during mid-day trading on Monday, reaching $7.92. 916,186 shares of the company traded hands, compared to its average volume of 1,753,659. The company’s 50 day moving average price is $7.61 and its 200-day moving average price is $7.53. The firm has a market cap of $1.64 billion, a PE ratio of -12.98 and a beta of 1.76. BioCryst Pharmaceuticals, Inc. has a 52 week low of $4.03 and a 52 week high of $8.88.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.07). The firm had revenue of $117.10 million during the quarter, compared to the consensus estimate of $113.99 million. The business’s revenue for the quarter was up 35.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.19) earnings per share. On average, research analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.38 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

BCRX has been the topic of a number of recent analyst reports. Needham & Company LLC reaffirmed a “buy” rating and set a $14.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. Royal Bank of Canada reissued an “outperform” rating and set a $10.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. Finally, Barclays upped their price objective on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 5th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $15.60.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.